Syncom formulations Share Price Target 2025, 2026, 2027, 2028, 2030:- Syncom Formulations is a global pharmaceutical company that manufactures and markets a wide range of healthcare products. Today, we will try to analyze the entire business of Syncom Formulations to see how far its business can go in the future.
In this article, we will attempt to analyze every small detail about the shares of Syncom Formulations in our own way.
Syncom Formulations Share Price Target 2025
The company operates in the pharmaceutical, ethical, OTC (over-the-counter), and general market segments. It is involved in the manufacturing and production processes of pharmaceuticals, formulations, and other industries. It produces a range of products in various dosage forms and has a market presence in different countries. In addition to manufacturing medications in the form of tablets, capsules, liquid formulations, and dry powders, the company also produces injections, inhalers, and eye or ear drops.
As for Syncom Formulations’ share price target in 2025, the initial target price is approximately ₹15, and by the end of the financial year, the target price is expected to be ₹19.
| Months | Syncom Formulations Share Price Target 2025 |
|---|---|
| January 2025 | 15 |
| February 2025 | 15.50 |
| March 2025 | 16 |
| April 2025 | 16.40 |
| May 2025 | 16.80 |
| June 2025 | 17 |
| July 2025 | 17.30 |
| August 2025 | 17.50 |
| September 2025 | 17.80 |
| October 2025 | 18.50 |
| November 2025 | 18.80 |
| December 2025 | 19 |
Syncom Formulations Share Price Target 2026
In discussing the history of Syncom Formulations, during the year 1997-98, the company once again introduced a series of prescription drugs, bringing diversity to its ethical portfolio. Notably, there was significant growth in established capacity and production during 1998-99. Additionally, the company presents products in standard, OTC, and ethical categories.
The perspective on the formulation of various products by Syncom has been validated by customer excellence worldwide. For the year 2026, the first share price target for Syncom Formulations is ₹19.50, and the second share price target is ₹25.
| Months | Syncom Formulations Share Price Target 2026 |
|---|---|
| January 2026 | 19.50 |
| February 2026 | 20 |
| March 2026 | 20.50 |
| April 2026 | 20.80 |
| May 2026 | 21.20 |
| June 2026 | 21.50 |
| July 2026 | 22 |
| August 2026 | 23 |
| September 2026 | 23.50 |
| October 2026 | 24 |
| November 2026 | 24.60 |
| December 2026 | 25 |
Syncom Formulations Share Price Target 2027
Syncom Formulations has taken the initiative to bring the beauty of traditional Indian medical science, Ayurveda, to humanity through its unique range of herbal products used for various medicinal and immunological purposes. These products serve as evidence across the world, benefiting countless patients by reducing various ailments and improving their quality of life. Currently, the company exports to Guinea, Ghana, Kenya, Uganda, Sudan, Russia, Moldova, Tanzania, Africa, Azerbaijan, Nepal, and Sri Lanka.
The initial target price for Syncom Formulations’ share in 2027 is ₹26, and for the second target, the share price will be ₹32.
| Months | Syncom Formulations Share Price Target 2027 |
|---|---|
| January 2027 | 26 |
| February 2027 | 27 |
| March 2027 | 27.50 |
| April 2027 | 28 |
| May 2027 | 28.40 |
| June 2027 | 28.80 |
| July 2027 | 29.50 |
| August 2027 | 30 |
| September 2027 | 30.50 |
| October 2027 | 31 |
| November 2027 | 31.50 |
| December 2027 | 32 |
Syncom Formulations Share Price Target 2028
Syncom Formulations has adapted to the changing medical landscape and entered the international market a decade ago. The headquarters for international operations is located in its international division in Mumbai, the commercial capital of India. Today, Syncom Formulations promotes all its standard, pharmaceutical, and OTC products in the markets where it operates. Syncom Formulations has a presence in Asia, Africa, CIS and Russia, and Latin American countries. The Mumbai office also has an administrative affairs department, equipped with a state-of-the-art library, reference documents, and all other resources to provide world-class registration documents.
The share price target for Syncom Formulations in 2028 is expected to be 33 rupees for the first share. For the 2027 financial year, the target price for the second share of Syncom Formulations is approximately 40 rupees.
| Months | Syncom Formulations Share Price Target 2028 |
|---|---|
| January 2028 | 33 |
| February 2028 | 34 |
| March 2028 | 34.50 |
| April 2028 | 35 |
| May 2028 | 36 |
| June 2028 | 36.60 |
| July 2028 | 37.20 |
| August 2028 | 37.80 |
| September 2028 | 38 |
| October 2028 | 38.50 |
| November 2028 | 39 |
| December 2028 | 40 |
Syncom Formulations Share Price Target 2030
The company is recognized as a supplier to prestigious hospitals and regulatory agencies, including the Central Medical Stores Organization of the Gujarat Government, the Delhi Government Health Service Unit, and the Central Government. The provision and registration of security services are in their final stages. This has resulted in a significant volume of sales. Considering the changing preferences of consumers towards herbal products, the company manufactures and markets pharmaceutical products such as Colo Vaporex, Colo Inhaler, Adicare, Atom Megacaps, Exiguard, and Yes Antacid Salt. In 2012, Syncom Formulations merged a wholly-owned subsidiary in the United Arab Emirates under the name “TRADE ZONE FZE.”
The share price target for Syncom Formulations in 2030 is expected to be 60 rupees for the first share. By the end of 2030, the target price for the second share is projected to be 75 rupees.
| Months | Syncom Formulations Share Price Target 2030 |
|---|---|
| January 2030 | 60 |
| February 2030 | 61 |
| March 2030 | 63 |
| April 2030 | 64 |
| May 2030 | 65 |
| June 2030 | 66 |
| July 2030 | 68 |
| August 2030 | 69 |
| September 2030 | 70 |
| October 2030 | 72 |
| November 2030 | 74 |
| December 2030 | 75 |
Future Prospects of Syncom Formulations Share
- Due to increasing revenue, greater health awareness, lifestyle-related diseases, and growing access to insurance, the Indian healthcare sector is expected to reach 372 billion USD by 2022. Healthcare has become one of the largest sectors in India in terms of income and employment. Therefore, to gain the maximum customer base, Syncom Formulations will need to come up with new products or medications.
- Syncom Formulations needs additional funding in the field of research and development to be able to reach new products or medications that are self-sufficient.
- Syncom Formulations needs to open plants in every corner of the world from where exports can be easily managed.
Expert Views on Syncom Formulations Share
Trend analysis indicates that Syncom Formulations Limited’s long-term stocks are strong and are naturally growing. Therefore, if you want to invest in Syncom Formulations Limited’s shares, you can continue with your investment.
Syncom Formulations Share F.A.Q.
– Who is the owner of Syncom Formulations?
The owner of Syncom Formulations is Kedarmal Shankarlal Bankda.
– Syncom Formulations is associated with the pharmaceutical business.
Syncom Formulations participates in the pharmaceutical industry.
Where is the headquarters of Syncom Formulations?
The headquarters of Syncom Formulations is in Maharashtra, India.
Conclusion
I hope that after reading the article on Syncom Formulations’ Share Price Target for 2025, 2026, 2027, 2028, and 2030, you now have an idea of the direction in which the company’s growth will likely trend in the coming years. If you still have any questions related to this post, please don’t hesitate to let me know in the comments. Stay connected with Market in India for updates on such important information related to the stock market.
Also read:- Vikas Ecotech Share Price Target 2025, 2026, 2027, 2030